Micropos Medical
Enabling accuracy in prostate cancer care
Micropos Medical is a Swedish medical device company that develops, manufactures, and sells technology enabling enhanced radiotherapy cancer treatment. Its product Raypilot® System, generates high precision as well as high efficiency through real-time tumour tracking in radiation treatment of prostate cancer. Raypilot is marketed in Europe and the US.
The Micropos Medical share is traded under the stock ticker MPOS on the Spotlight Stock Market.
For more information about the share, please visit Spotlight
Interim Reports
annual reports
Financial calendar
| DATE | EVENTS |
|---|---|
| 30 January 2026 | Interim report Q4/Year-end Report 2025 |
| 30 April 2026 | Interim report Q1 2026 |
| 21 May 2026 | Annual general meeting in Gothenburg |
| 31 July 2026 | Interim report Q2 2026 |
| 30 October 2026 | Interim report Q3 2025 |
| 29 January 2027 | Interim report Q4 2026 |
For additional information, please contact:
Richard Forsberg, CEO, Micropos Medical AB (publ)
+46-31-760 80 05, info@micropos.se
-
news
Micropos Medical Receives MDR Certification
We are proud to announce that Micropos Medical AB has received the MDR as well as the UKCA certificate for the Raypilot System. This certification confirms that Micropos Medical’s Raypilot System is […]
COMPANY INFO
LEARN MORE ABOUT OUR TEAM, BOARD AND OUR PRODUCTS
NEWSLETTER
Follow us on LinkedIn
Let’s keep in touch